Cargando…
The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye
PURPOSE: To compare OTX-DED, an investigational dexamethasone intracanalicular insert, to loteprednol 0.5% suspension applied QID for 28 days as treatments for acute exacerbations of dry eye disease in terms of patient symptoms, corneal staining, tear breakup time (TBUT), and ocular redness. METHODS...
Autores principales: | Hovanesian, John A, Keyser, Andrew, Berdy, Gregg, Sorensen, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698338/ https://www.ncbi.nlm.nih.gov/pubmed/36438591 http://dx.doi.org/10.2147/OPTH.S387111 |
Ejemplares similares
-
Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022) -
Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020) -
Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John A, et al.
Publicado: (2021) -
Dry Eye Disease = DED = A Disease Eluding Diagnosis
por: Honavar, Santosh G
Publicado: (2023) -
Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
por: Sy, Aileen, et al.
Publicado: (2015)